Stephen C Kales
Overview
Explore the profile of Stephen C Kales including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
692
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shrimp J, Kales S, Sanderson P, Simeonov A, Shen M, Hall M
ACS Pharmacol Transl Sci
. 2020 Oct;
3(5):997-1007.
PMID: 33062952
SARS-CoV-2 is the viral pathogen causing the COVID19 global pandemic. Consequently, much research has gone into the development of preclinical assays for the discovery of new or repurposing of FDA-approved...
12.
Shrimp J, Kales S, Sanderson P, Simeonov A, Shen M, Hall M
bioRxiv
. 2020 Jun;
PMID: 32596694
SARS-CoV-2 is the viral pathogen causing the COVID19 global pandemic. Consequently, much research has gone into the development of pre-clinical assays for the discovery of new or repurposing of FDA-approved...
13.
Brimacombe K, Zhao T, Eastman R, Hu X, Wang K, Backus M, et al.
bioRxiv
. 2020 Jun;
PMID: 32511420
The National Center for Advancing Translational Sciences (NCATS) has developed an online open science data portal for its COVID-19 drug repurposing campaign - named OpenData - with the goal of...
14.
Daniels S, Liyasova M, Kales S, Nau M, Ryan P, Green J, et al.
PLoS One
. 2019 Jul;
14(7):e0219143.
PMID: 31260484
Receptor Tyrosine Kinase (RTK) signaling is essential for normal biological processes and disruption of this regulation can lead to tumor initiation and progression. Cbl proteins (Cbl, Cbl-b and Cbl-c) are...
15.
Semple S, Heath G, Christie D, Braunstein M, Kales S, Dixon B
Immunogenetics
. 2019 May;
71(5-6):407-420.
PMID: 31037384
Major histocompatibility complex (MHC) class II-associated invariant chain is a chaperone responsible for targeting the MHC class II dimer to the endocytic pathway, thus enabling the loading of exogenous antigens...
16.
Hinohara K, Wu H, Vigneau S, McDonald T, Igarashi K, Yamamoto K, et al.
Cancer Cell
. 2019 Feb;
35(2):330-332.
PMID: 30753830
No abstract available.
17.
Liu X, Zhang S, McGeary M, Krykbaeva I, Lai L, Jansen D, et al.
Mol Cancer Ther
. 2018 Dec;
18(3):706-717.
PMID: 30523048
Tumor heterogeneity is a major challenge for cancer treatment, especially due to the presence of various subpopulations with stem cell or progenitor cell properties. In mouse melanomas, both CD34p75 (CD34)...
18.
Hinohara K, Wu H, Vigneau S, McDonald T, Igarashi K, Yamamoto K, et al.
Cancer Cell
. 2018 Nov;
34(6):939-953.e9.
PMID: 30472020
Members of the KDM5 histone H3 lysine 4 demethylase family are associated with therapeutic resistance, including endocrine resistance in breast cancer, but the underlying mechanism is poorly defined. Here we ...
19.
Horton J, Woodcock C, Chen Q, Liu X, Zhang X, Shanks J, et al.
J Med Chem
. 2018 Nov;
61(23):10588-10601.
PMID: 30392349
The active sites of hundreds of human α-ketoglutarate (αKG) and Fe(II)-dependent dioxygenases are exceedingly well preserved, which challenges the design of selective inhibitors. We identified a noncatalytic cysteine (Cys481 in...
20.
Wu L, Cao J, Cai W, Lang S, Horton J, Jansen D, et al.
PLoS Biol
. 2018 Aug;
16(8):e2006134.
PMID: 30080846
Cyclic GMP-AMP (cGAMP) synthase (cGAS) stimulator of interferon genes (STING) senses pathogen-derived or abnormal self-DNA in the cytosol and triggers an innate immune defense against microbial infection and cancer. STING...